Home > Haematology > B-cell lymphoma might respond to N-myristoyltransferase inhibition

B-cell lymphoma might respond to N-myristoyltransferase inhibition

Journal
Nature Communications
Reuters Health - 26/11/2020 - Targeting N-myristoylation might prove to be an effective treatment for B-cell lymphoma and other cancers, according to a preclinical study. Myristoylation, the N-terminal modification of proteins mediated by N-myristoyl-transferase (NMT), plays a key role in cell signaling and allows for dynamic interactions of proteins with cell membranes. NMT expression levels and activity are increased in some cancers. Dr. Luc G. Berthiaume of the University of Alberta and Pacylex Pharmaceuticals Inc., in Edmonton, Canada, and colleagues tested the sensitivity of 300 cancer cell lines encompassing all major cancer types to NMT inhibition with the orally bioavailable small-molecule inhibitor PCLX-001. PCLX-001 inhibited the viability and growth of nearly all types of cancer cell lines tested, but it inhibited hematological cancer cells in vitro more effectively than it did other cancer cell types or select normal cells, the researchers report ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on